Chronic myeloid leukemia (CML) is a clonal myeloproliferative disease characterized by a reciprocal translocation between long arms of chromosomes 9 and 22 t(9;22) that generates the BCR-ABL fusion gene. If left untreated, newly diagnosed chronic phase CML patients finally progress to accelerated and blastic phase. After the introduction of tyrosine kinase inhibitors (TKIs), treatment strategie...

in chronic myelogenous leukemia (cml), the mature granulocytes originate from a stem cell line harboring an abnormal chromosome, therefore it is possible that metabolic-functional abnormalities occur in the morphologically mature cells. in the present study, the phagocytic activity including intracellular killing, nitro blue tetrazolium (nbt) reduction, and phagocytosis were studied in 37 cml p...

Plasma and urine levels of cyclic adenosine 3',5'-monophosphate (cAMP) and of cyclic guanosine 3',5'-monophosphate (cGMP) were measured in 35 normal subjects, in 24 patients with nonneoplastic diseases (iron deficiency anemia, peptic ulcer, and cholelithiasis), and in 50 leukemic patients. The leukemic group included patients with acute lymphoblastic leukemia, acute myelogenous leukemia, chroni...

Figure 1. Leukemic cell morphology of bone marrow aspiration specimen (May-Grünwald-Giemsa). An 82-year-old woman was admitted to our hospital presenting with febrile neutropenia. She had been diagnosed with chronic myeloid leukemia 2 years ago and had been on imatinib treatment since [1]. A month before admission she presented with malaise, anemia, and mild leukopenia; a bone marrow aspirate a...

The previously uncharacterized CDC24 homology domain of BCR, which is missing in the P185 BCR-ABL oncogene of Philadelphia chromosome (Ph1)-positive acute lymphocytic leukemia but is retained in P210 BCR-ABL of chronic myelogeneous leukemia, was found to bind to the xeroderma pigmentosum group B protein (XPB). The binding appeared to be required for XPB to be tyrosine-phosphorylated by BCR-ABL....

The natural course of chronic myelogenous leukemia (CML) has changed dramatically since the introduction of tyrosine kinase inhibitors (TKIs) with 490% of the patients achieving long-term disease control. Development of resistance with progression to accelerated phase/blastic crisis (AP/BC) is observed in a limited percentage of patients and is mainly documented in those who do not respond ‘opt...

The surface antigen phenotype of 30 patients with the blast phase of chronic myeloid leukemia (CML) was determined using a panel of monoclonal antibodies recognizing differentiation antigens of normal myeloid, erythroid, megakaryocyte, and lymphoid cells. Ten patients' cells expressed a phenotype corresponding to an immature myeloid cell and were felt to have "myeloid" blast crisis. None of the...

Y. M. Chin, BSc (Hon) Haemotology Department Khalid Hassan, MBBS. MRCP, MRCPath, DCP, DTMH Head, Haemotology Department, Institute for Medical Research Kuala Lumpur have to be subjected to in vitro culture and stimulated with mitogens such as phytohaemagglutinin in order to obtain dividing cells for chromosome analysis. This is the standard method employed in karyotyping an individual. In leuke...

Experiences with new multikinase inhibitors are limited, especially in children. In this report we summarize our experience with 2 patients with relapsed acute myeloblastic leukemia (AML), one with FMS-like tyrosine kinase-3-internal tandem duplication mutation and the other with a single base mutation (D835Y). Both patients received sorafenib, one for 19 days and the other for 42 days, with cl...